| Q73784645 | A follow up study of suicide attempters: increase of CSF-somatostatin but no change in CSF-CRH |
| Q33604477 | A review of endocrine changes in anorexia nervosa. |
| Q89575924 | A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders |
| Q40780751 | Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention |
| Q28568340 | Antidepressants influence somatostatin levels and receptor pharmacology in brain |
| Q35808924 | Biosynthesis of somatostatin in canine fundic D cells |
| Q39472153 | Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness. An overview |
| Q38221334 | Central and peripheral peptides regulating eating behaviour and energy homeostasis in anorexia nervosa and bulimia nervosa: a literature review |
| Q34060773 | Cholecystokinin and panic disorder--three unsettled questions |
| Q47737537 | Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy |
| Q39750053 | Cholecystokinin and schizophrenia |
| Q51097201 | Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour. |
| Q42510108 | Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens |
| Q48126049 | Circadian neuroendocrine functions in disorders of eating behavior |
| Q48754447 | Decreased cholecystokinin levels in cerebrospinal fluid of patients with adult chronic hydrocephalus syndrome |
| Q52348833 | Differential plastic changes in synthesis and binding in the mouse somatostatin system after electroconvulsive stimulation. |
| Q48593236 | Effects of acute and chronic desipramine treatment on somatostatin receptors in brain |
| Q48584590 | Effects of carbamazepine on cerebrospinal fluid somatostatin |
| Q73484104 | Effects of galanin on growth hormone and prolactin secretion in anorexia nervosa |
| Q48634555 | Effects of somatostin on food intake in rats |
| Q36091591 | Endocrine disturbances in depression |
| Q47963605 | Enhanced response of growth hormone to growth hormone-releasing hormone and a decreased content of hypothalamic somatostatin in a stress-induced rat model of depression |
| Q36888642 | GH/IGF-I axis in anorexia nervosa |
| Q36637152 | Ghrelin: central and peripheral implications in anorexia nervosa |
| Q73590867 | Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa |
| Q48311559 | How to measure cholecystokinin in tissue, plasma and cerebrospinal fluid |
| Q43952030 | Indirect evidence for decreased hypothalamic somatostatinergic tone in anorexia nervosa |
| Q40961269 | Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications |
| Q36756393 | Involvement of neuropeptide systems in schizophrenia: human studies |
| Q35221134 | Is anorexia nervosa a neuropsychological disease? |
| Q69896252 | Lack of effect of chronic carbamazepine on brain somatostatin in the rat |
| Q49096077 | Low levels of somatostatin in human CSF mark depressive episodes |
| Q58591605 | MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and endocrinology: A clinical update |
| Q48788188 | Meningeal cells are targets and inactivation sites for the neuropeptide somatostatin |
| Q39468402 | Neuroactive substances in cerebrospinal fluid. Normal and pathological regulatory mechanisms |
| Q38153758 | Neuroendocrine changes in depression |
| Q37731491 | Neuroendocrine dysfunction in psychotic disorders (excluding ACTH). |
| Q52080972 | Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies. |
| Q34052805 | Neuropathology of bipolar disorder |
| Q35130197 | Neuropeptides involved in the pathophysiology of schizophrenia and major depression |
| Q39498368 | Neuropeptides, behavior, and aging |
| Q39548116 | Neuropeptides, dopamine, and schizophrenia |
| Q36501962 | Neurotransmitters and Neuropeptides in Alzheimer's Disease |
| Q36534909 | Non-endocrine applications of somatostatin and octreotide acetate: facts and flights of fancy |
| Q35575099 | Nutritional status in the neuroendocrine control of growth hormone secretion: the model of anorexia nervosa |
| Q44588510 | Physiological release of striatal acetylcholine (in vivo): effect of somatostatin on dopaminergic-cholinergic interaction |
| Q51579031 | Pre- and postprandial pyridostigmine and oxiracetam effects on growth hormone secretion in anorexia nervosa. |
| Q48578177 | Reduced cholecystokinin levels in the limbic lobe in schizophrenia. A marker for pathology underlying the defect state? |
| Q44945166 | Sensitivity to cholecystokinin-tetrapeptide in major depression |
| Q47280880 | Serum insulin but not leptin is associated with spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in normal volunteers with and without weight loss |
| Q33631143 | Somatostatin content and receptors in the cerebral cortex of depressed and control subjects |
| Q46394491 | Somatostatin increases rat locomotor activity by activating sst(2) and sst (4) receptors in the striatum and via glutamatergic involvement |
| Q46420911 | Somatostatin-like immunoreactivity in CSF of schizophrenic patients during haloperidol treatment |
| Q40168561 | Stress-induced anorexia: Implications for anorexia nervosa |
| Q48620377 | The effects of corticotropin-releasing hormone on peptidergic neurons in the rat forebrain |
| Q59619291 | The influence of human corticotropin-releasing hormone on somatostatin secretion in depressed patients and controls |
| Q39663919 | The role of peptides in affective disorders: a review. |